Document is current

Article History

Received: 23 January 2025

Accepted: 26 June 2025

First Online: 28 July 2025

Change Date: 1 August 2025

Change Type: Update

Change Details: Quality of graphical abstract improved

Declarations

:

: Amy S Paller has served as an investigator for AbbVie, Applied Pharma Research, Biomendics, Dermavant, Eli Lilly, Incyte, Janssen, Krystal, Regeneron, Timber, and UCB; a consultant for Abeona, Apogee, Arcutis, Aslan, BioCryst, Boehringer-Ingelheim, Castle Creek, Bristol-Myers-Squibb, Dermavant, Incyte, Krystal, LEO, L’Oreal, Mitsubishi Tanabe, MoonLake Immunotherapeutics, Procter and Gamble, Regeneron, Sanofi, Seanergy, and UCB; and on the data safety monitoring board for AbbVie, Abeona, Biocryst, Daiichi Sankyo, and Galderma. Andrew Blauvelt has served as a speaker (received honoraria) for Eli Lilly and Company and UCB, has served as a scientific adviser (received honoraria) for AbbVie, Abcentra, Aclaris, Affibody, Aligos, Almirall, Alumis, Amgen, Anaptysbio, Apogee, Arcutis, Arena, Aslan, Athenex, Bluefin Biomedicine, Boehringer Ingelheim, Bristol Myers Squibb, Cara Therapeutics, Celldex, CTI BioPharma, Dermavant, EcoR1, Eli Lilly and Company, Escient, Evelo, Evommune, Forte, Galderma, HighlightII Pharma, Incyte, InnoventBio, Janssen, Landos, LEO Pharma, Lipidio, Microbion, Merck, Monte Rosa Therapeutics, Nektar, Novartis, Overtone Therapeutics, Paragon, Pfizer, Q32 Bio, Rani, Rapt, Regeneron, Sanofi Genzyme, Spherix Global Insights, Sun Pharma, Takeda, TLL Pharmaceutical, TrialSpark, UCB Pharma, Union, Ventyx, Vibliome, and Xencor; has acted as a clinical study investigator (institution has received clinical study funds) for AbbVie, Acelyrin, Allakos, Almirall, Alumis, Amgen, Arcutis, Athenex, Boehringer Ingelheim, Bristol-Myers Squibb, Concert, Dermavant, DermBiont, Eli Lilly and Company, Evelo, Evommune, Galderma, Incyte, Janssen, LEO Pharma, Merck, Novartis, Pfizer, Regeneron, Sanofi, Sun Pharma, Takeda, UCB Pharma, and Ventyx; and owns stock in Lipidio and Oruka. Weily Soong reports grants from LEO Pharma during the conduct of the study; personal fees from LEO Pharma, Regeneron, Sanofi, Genentech, Lilly, AbbVie, Pfizer, Amgen, and AstraZeneca; grants from Regeneron, Genentech, Lilly, Glenmark, Allakos, AbbVie, Pfizer, Incyte, Aslan, and Amgen; serving on the advisory boards of and receiving research grants from Incyte, Lilly, Genentech, Novartis, and UCB; serving on the advisory boards, receiving research grants, and serving as a speaker for AbbVie, LEO Pharma, Amgen, AstraZeneca, Pfizer, Regeneron, and Sanofi; and receiving research grants from Allakos, Dermavant. Galderma. H. Chih-ho Hong has received honoraria as a speaker/consultant for Abbvie, Amgen, Arcutis, ASLAN pharmaceutics, Bausch Health, Boehringer-Ingelheim, Bristol Meyers Squibb, Celgene, Dermavant, Eli-Lilly, Galderma, GSK, Incyte, Janssen, LEO Pharma, Novartis, Pfizer, Regeneron, Sanofi-Genzyme, Sun Pharma, and UCB; and has received grants as an investigator from Abbvie, Amgen, Arcutis, Bausch Health, Boehringer-Ingelheim, Bristol Meyers Squibb, Celgene, Cutanea, Dermira, Dermavant, DS Biopharma, Eli Lilly, Evelo Biosciences, Galderma, GSK, Incyte, Janssen, LEO Pharma, Medimmune, Merck, Mirimar, Novartis, Pfizer, Regeneron, Sanofi-Genzyme, Roche, and UCB. Marie LA Schuttelaar reports support from LEO Pharma as an investigator during the conduct of the study; has received honoraria as an adviser/consultant/speaker for LEO Pharma, Sanofi/Genzyme, Eli Lilly, AbbVie, Galderma; received research grants from Sanofi/Genzyme, Pfizer, and Novartis. Shannon KR Schneider is an employee of LEO Pharma Inc. Eric L Simpson reports personal fees from AbbVie, Amgen, Arena Pharmaceuticals, Aslan Pharma, Benevolent AI Bio Limited “BAI”, BiomX Ltd, Bluefin Biomedicine Inc, Boehringer-Ingelheim, Boston Consulting Group, Collective Acumen, LLC (CA), Coronado, Dermira, Eli Lilly, Evidera, ExcerptaMedica, Galderma, GlaxoSmithKline, Forte Bio RX, Incyte Dermatologics, Janssen, Kyowa Kirin Pharmaceutical Development, LEO Pharma, Medscape LLC, Merck, Novartis, Ortho Galderma, Pfizer, Physicians World LLC, Pierre Fabre Dermo Cosmetique, Regeneron, Roivant, Sanofi- Genzyme, SPARC India, Trevi therapeutics, WebMD and Valeant; reports grants (or served as Principal Investigator role) from AbbVie, Amgen, Arcutis, Aslan, Castle Biosciences, Inc Celegene, CorEvitas, Dermavant, Dermira, Eli Lilly, Galderma, Incyte, Kymab, Kyowa Hakko Kirin, LEO Pharma, Merck, Novartis, Pfizer, Regeneron, Sanofi, and TARGET-DERM.

: The trial protocol was approved by all relevant ethics committees and institutional review boards (see Supplementary Table S4). The trial was conducted according to the principles of the Declaration of Helsinki and the International Council on Harmonization Guidelines for Good Clinical Practice and conformed with all relevant country-specific laws and regulations. All patients, or their legal representatives, provided written informed consent.